Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZT-OP1 in Alzheimer's Disease and Healthy Volunteers
NCT04570644Phase 1Completed
- Sponsor
- AZTherapies
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium cromoglycate and ibuprofen in Alzheimer's disease (AD) (4 arms), sponsored by AZTherapies. Primary endpoint: Pharmacokinetic parameters (AUC, Cmax, CL/F, t1/2, tmax, Vd/F) for ALZT-OP1a and ALZT-OP1b in plasma and CSF at 2 Days. Started Aug 2020; status: completed.
02
Drugs
sodium cromoglycateibuprofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04570644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570644.